Proactive Planning for Respiratory Season: It's Time to Rethink Your COVID-19 Testing Strategy
By Scott Robitaille, CCO
Understanding the Current Context
Despite the reprieve offered by the summer season, it is important for healthcare professionals to be mindful of the approaching respiratory season. This is a time when respiratory viruses, including the common cold, influenza, RSV, Strep-A, and notably, COVID-19, often peak. The period typically falls between early fall and spring. Therefore, summer offers an opportune moment to anticipate and prepare for this inevitable surge in demand.
Considering New Strategies
Given the current low levels of COVID-19 infections and testing, you may have missed Thermo Fisher Scientific's discontinuation of the Accula™ product line on April 11, 2023. Your supply of Accula tests may have expired or are being depleted as the summer progresses, and restocking is no longer an option. This predicament heightens the urgency of identifying a viable COVID-19 testing strategy alternative. The AscencioDx® COVID-19 Test and Molecular Detector is a viable solution.
Exploring the Advantages of AscencioDx
Anavasi's AscencioDx is a revolutionary molecular platform that seamlessly combines compact design, speed, and accuracy. It not only has numerous advantages over prior market offerings, including Accula, but also sets a new standard for convenience, speed, and versatility.
Key characteristics and benefits of the AscencioDx:
Rapid Results: AscencioDx delivers positive test results in as few as 20-minutes, thus expediting decision-making and enhancing patient care.
Environmentally Friendly: In line with our commitment to sustainable practices, AscencioDx has been designed to minimize environmental impact. Its lightweight disposable components and reusable device substantially decreases biowaste.
Easy and Convenient: The CLIA-waived AscencioDx system is incredibly user-friendly and does not require extensive training for operators, making it a suitable choice for all healthcare settings.
Efficient Reporting: AscencioDx simplifies test reporting and patient records with its dynamic QR code scanning feature, which allows for effortless logging of test results to our cloud-based Anavasi Detector Portal.
Quality You Can Rely On: AscencioDx is FDA EUA authorized and proudly made in the United States to our strict quality standards.
Planning the Next Steps
The period leading up to the respiratory season is the optimal time to invest in point-of-care facilities and complete staff training. With the recent lull in testing activity, even seasoned employees may need a refresher. The comprehensive introduction process provided by Anavasi includes personalized training, product videos, and a certification assessment.
As an added benefit for former Accula users, Anavasi offers a swap-out program in which Accula workstations can be exchanged for Ascencio Detectors at no additional cost. Additionally, Anavasi offers competitive introductory pricing to facilitate a seamless transition. For more information, we encourage you to contact our sales team at sales@anavasidx.com or (888) 262-8274.
Proactive planning can help ensure your team is well-prepared for the upcoming respiratory season.
The AscencioDx® Covid-19 Test and The AscencioDx® Molecular Detector have not been FDA cleared or approved, but have been authorized for emergency use by FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.